Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease - Test2 - elhamkhani - TriplyDB

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease

http://www.wikidata.org/entity/Q24324577

about

Genetic perspective on the role of the autophagy-lysosome pathway in Parkinson disease Deconvoluting the complexity of autophagy and Parkinson's disease for potential therapeutic purpose Glucocerebrosidase and Parkinson disease: Recent advances Glucocerebrosidase 1 deficient Danio rerio mirror key pathological aspects of human Gaucher disease and provide evidence of early microglial activation preceding alpha-synuclein-independent neuronal cell death Viable neuronopathic Gaucher disease model in Medaka (Oryzias latipes) displays axonal accumulation of alpha-synuclein Dysregulation of autophagy and mitochondrial function in Parkinson's disease Mitochondrial dysfunction associated with glucocerebrosidase deficiency Upregulation and axonal transport of synaptotagmin-IV in the direct-pathway medium spiny neurons in hemi-parkinsonian rats induced by dopamine D1 receptor stimulation Exploring the Effects of Genetic Variants on Clinical Profiles of Parkinson's Disease Assessed by the Unified Parkinson's Disease Rating Scale and the Hoehn-Yahr Stage Mitochondrial lipids in neurodegeneration Gene-wise association of variants in four lysosomal storage disorder genes in neuropathologically confirmed Lewy body disease LIMP-2 expression is critical for β-glucocerebrosidase activity and α-synuclein clearance A Review of Gaucher Disease Pathophysiology, Clinical Presentation and Treatments Affinity of Tau antibodies for solubilized pathological Tau species but not their immunogen or insoluble Tau aggregates predicts in vivo and ex vivo efficacy.Factors influencing the measurement of lysosomal enzymes activity in human cerebrospinal fluid Macrophage models of Gaucher disease for evaluating disease pathogenesis and candidate drugs.Pathways to Parkinsonism Redux: convergent pathobiological mechanisms in genetics of Parkinson's disease.Alpha-synuclein function and dysfunction on cellular membranes.Structural features of membrane-bound glucocerebrosidase and α-synuclein probed by neutron reflectometry and fluorescence spectroscopy.Loss of glucocerebrosidase 1 activity causes lysosomal dysfunction and α-synuclein aggregation.Variants associated with Gaucher disease in multiple system atrophy.Progressive decline of glucocerebrosidase in aging and Parkinson's disease.Selective loss of glucocerebrosidase activity in sporadic Parkinson's disease and dementia with Lewy bodies.Gaucher-Associated Parkinsonism.Lysosomal Enzyme Glucocerebrosidase Protects against Aβ1-42 Oligomer-Induced Neurotoxicity.Glucocerebrosidase Deficiency in Drosophila Results in α-Synuclein-Independent Protein Aggregation and Neurodegeneration.Sustained Systemic Glucocerebrosidase Inhibition Induces Brain α-Synuclein Aggregation, Microglia and Complement C1q Activation in Mice.Glucocerebrosidase activity in Parkinson's disease with and without GBA mutations Mannose 6-Phosphate Receptor Is Reduced in -Synuclein Overexpressing Models of Parkinsons Disease.Elevated GM3 plasma concentration in idiopathic Parkinson's disease: A lipidomic analysis Applications of iPSC-derived models of Gaucher disease Acidic Ca2+ stores in neurodegeneration.GBA deficiency promotes SNCA/α-synuclein accumulation through autophagic inhibition by inactivated PPP2A.Age- and brain region-dependent α-synuclein oligomerization is attributed to alterations in intrinsic enzymes regulating α-synuclein phosphorylation in aging monkey brains.Distinct Lysosomal Network Protein Profiles in Parkinsonian Syndrome Cerebrospinal Fluid.A New Glucocerebrosidase Chaperone Reduces α-Synuclein and Glycolipid Levels in iPSC-Derived Dopaminergic Neurons from Patients with Gaucher Disease and Parkinsonism.A new glucocerebrosidase-deficient neuronal cell model provides a tool to probe pathophysiology and therapeutics for Gaucher disease.Strong association between glucocerebrosidase mutations and Parkinson's disease in Sweden.Parkinson disease-linked GBA mutation effects reversed by molecular chaperones in human cell and fly models.Blood Plasma of Patients with Parkinson's Disease Increases Alpha-Synuclein Aggregation and Neurotoxicity.

P2860

cddd3601da57ca455b646b78afe29a711e52c5e6

P248

Q22242985-5C3D7F16-529A-41DF-B669-FD49BB43B1A0 Q26785491-6872ADDF-0F4E-44C4-A177-C37715192675 Q27005669-852D83E7-36A1-4DAE-81C9-9A3566449C83 Q27300869-EE14DCAE-74BF-4C3B-B4FA-994AAA4AA3A2 Q27311396-2C48187A-599C-4570-B141-B8137B52EAED Q28071890-CE5CF98D-0820-44B9-8A01-244F4AFDD70B Q28115678-6303A62C-C498-4537-910A-9E4AE71CC820 Q28115869-979FE34A-1F6E-44E4-A178-228830B7A6D5 Q28396892-17392BA6-1922-499B-AD40-4ED74C1C4094 Q28397548-B3FA7994-F6C4-4F73-B14B-7255C7D49970 Q28546902-02C04FA3-9666-468E-8F8B-A0DD6621BBBD Q28588670-407851A9-76BD-4348-8080-CF434FB1B3A2 Q30235844-11B68DE4-871D-4178-B2ED-0B8AC4619D8A Q30805841-0053B0DA-0F26-4AA9-AC63-E01F795D8AE8 Q33831118-B1440975-E649-495B-94C5-A060FE37296A Q34165147-A91338FC-0356-4DE0-BB75-00E781523F8D Q34481921-1D34761F-B52B-4903-9DF9-B9DC404B1E83 Q34774324-E9C89878-E206-4F0D-89DC-26D430D980B2 Q34964902-ED576322-28C2-4BE2-A225-3E3A23469680 Q35152964-6449A594-CD62-4E1C-93FA-A903BD4F8355 Q35469633-2BF2F597-6CDA-4F09-958B-366FC80B85F9 Q35469684-3DFBE0F2-884F-4CD9-BE05-36D3B6443592 Q35596071-B447FC77-EB1E-4217-8377-F11967DF990D Q35851610-D9EB3ED1-787B-4D46-A143-D40CAFFF88A4 Q35858682-FABF60A2-9A4A-47BF-8E57-34C49140685A Q35971649-923F056D-1085-41DE-8E1E-147270DFADA8 Q35982198-1F139CEC-0C67-4DFF-B925-8462EEA0C9EB Q36041420-665B1A50-B701-4AA3-B312-939D99EE546A Q36100354-97A419B1-F99A-469C-BE21-187CEB4BAA66 Q36284241-DE0C28D8-F4A6-4882-BD5A-E45B9F8AFBC3 Q36352522-C0E18259-1C88-4E19-9D4A-390B6A41358C Q36395510-0F94E7BA-C77F-4179-8314-0DDD6176DD24 Q36777244-27E3D800-2773-452C-B0FA-76D23616DC96 Q36962314-856BAADC-2685-47EA-A654-6A405124E30C Q37054024-AC76B90B-696B-46C0-B7AD-87BC2413B93A Q37096051-E0F8601E-0E4C-4F2B-818D-2BBE3A04CBBB Q37120413-A3399778-CB2D-4854-A696-0E7C56467523 Q37170658-1216CF1C-6479-4818-857F-DE33D23C7E13 Q37189019-0E4FAC43-AA84-474F-A9E9-B328F956A98B Q37443736-28040A06-8DC6-4506-B9AC-716DF04B0F49

P2860

Reduced glucocerebrosidase is associated with increased α-synuclein in sporadic Parkinson's disease

http://www.wikidata.org/entity/Q24324577

description

2014 nî lūn-bûn

@nan

2014 թուականի Մարտին հրատարակուած գիտական յօդուած

@hyw

2014 թվականի մարտին հրատարակված գիտական հոդված

@hy

2014年の論文

@ja

2014年論文

@yue

2014年論文

@zh-hant

2014年論文

@zh-hk

2014年論文

@zh-mo

2014年論文

@zh-tw

2014年论文

@wuu

name

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@ast

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@en

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@en-gb

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@nl

type

label

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@ast

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@en

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@en-gb

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@nl

prefLabel

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@ast

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@en

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@en-gb

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@nl

P1433

Q24324577-9F8B2931-859F-431D-9E83-0787532BAE06

P1476

Q24324577-C85E8777-3935-402B-A95A-455B4F2763E6

P2093

Q24324577-0D4F2015-F799-4F15-AFA0-115A481212AC

Q24324577-27AD3CB8-D66C-4201-B447-5D0B81115A7F

Q24324577-2B1EEE03-912A-4AE2-8E85-FC1B023D345D

Q24324577-41B23EF1-4AAA-4CB7-833B-CECE93E09188

Q24324577-5F1F6585-2DD1-4850-8C15-6AFB7C82ADDA

Q24324577-5F997461-C01E-4E29-A011-28450FC8273B

Q24324577-79B2F835-0BF0-44B9-A951-CC20DB5C12CB

Q24324577-E6419282-5F19-4B8C-8B62-E3CC8C33841A

P2860

Q24324577-068C8908-145E-4E80-BDC5-1330BC3ADF10

Q24324577-0E2A663F-8567-4B62-82C6-7CDE8CAFEAB4

Q24324577-10AC1058-E0AF-4B28-9BB9-A5FAA9C6C0E1

Q24324577-1254C2D7-91E2-4E29-9BB2-99036DEF58C0

Q24324577-236B7473-3A0C-41A8-B7E7-3072C07E3702

Q24324577-25420E0D-3D3C-4981-9C7C-BBCA3D96B95F

Q24324577-2658964A-8CF6-4763-83CC-167991F52C18

Q24324577-2A9A8FD8-3204-48EF-9E69-1F5585977E90

Q24324577-2C2D8BEA-11BB-467E-8088-7E326CD99F20

Q24324577-2E38F412-DBBE-4BA9-A88B-D38B1DBF5C6E

P304

Q24324577-6BC701CB-EDB6-4C0D-8397-25E2114DF0F2

P31

Q24324577-F95F1A9E-6B72-49F3-8856-327AC8653F5B

P3181

Q24324577-86D5AB3F-37B1-4B68-B611-55813FE88E6E

P356

Q24324577-A082D369-8ACE-4F28-AB33-07A65C9317A6

P407

Q24324577-CFF849B7-A66D-4705-A804-3B242A3329A5

P433

Q24324577-9173AE52-9968-4B15-9F43-13E8D50B3AFC

P478

Q24324577-DAD96961-05B7-40FE-ABB5-02B08857D2D4

P50

Q24324577-E6860C64-6342-4E09-812F-7BB2D2427A0C

P577

Q24324577-3AE0FFFF-2C45-40F1-8E73-54B9CB36498B

P698

Q24324577-71766CE4-2FAD-432C-81D1-BCEC1AFCC24E

P921

Q24324577-1F7D6881-9950-47C6-9D09-9CDE7013C61A

Q24324577-2BD46D36-EB6D-40DC-980C-E272A472F279

Q24324577-62149D8E-2460-449E-A273-8BDD5B02B52F

P932

Q24324577-F8BBBC52-C403-40DE-B620-A0A6696A6038

P3181

P356

P1433

P1476

Reduced glucocerebrosidase is ...... n sporadic Parkinson's disease

@en

P2093

Amanda M Gysbers

http://www.w3.org/2001/XMLSchema#string

Antony Cooper

http://www.w3.org/2001/XMLSchema#string

Brett Garner

http://www.w3.org/2001/XMLSchema#string

Ellen Sidransky

http://www.w3.org/2001/XMLSchema#string

Karen E Murphy

http://www.w3.org/2001/XMLSchema#string

Nahid Tayebi

http://www.w3.org/2001/XMLSchema#string

Sarah K Abbott

http://www.w3.org/2001/XMLSchema#string

Woojin S Kim

http://www.w3.org/2001/XMLSchema#string

P2860

LIMP-2 is a receptor for lysosomal mannose-6-phosphate-independent targeting of beta-glucocerebrosidase

Gaucher disease glucocerebrosidase and α-synuclein form a bidirectional pathogenic loop in synucleinopathies

Lysosomal hydrolases of different classes are abnormally distributed in brains of patients with Alzheimer disease

RAB7L1 interacts with LRRK2 to modify intraneuronal protein sorting and Parkinson's disease risk

Cathepsin A regulates chaperone-mediated autophagy through cleavage of the lysosomal receptor

Multicenter analysis of glucocerebrosidase mutations in Parkinson's disease.

The sphingolipid salvage pathway in ceramide metabolism and signaling

Glucocerebrosidase mutations in clinical and pathologically proven Parkinson's disease

Dopamine-modified alpha-synuclein blocks chaperone-mediated autophagy

Chaperone-mediated autophagy markers in Parkinson disease brains

P304

834-48

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

821912

http://www.w3.org/2001/XMLSchema#string

P356

10.1093/BRAIN/AWT367

http://www.w3.org/2001/XMLSchema#string

P407

P433

Pt 3

http://www.w3.org/2001/XMLSchema#string

P478

137

http://www.w3.org/2001/XMLSchema#string

P50

Glenda Halliday

P577

2014-03-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

24477431

http://www.w3.org/2001/XMLSchema#string

P921

Parkinson's disease

Synuclein alpha

P932

3927701

http://www.w3.org/2001/XMLSchema#string